Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003994 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 277
- Enrollment target
NCT00003994 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 277 participants.
The verdict
NCT00003994, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 277 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. It is not yet known which chemotherapy regimen is most effective for children and young adults with liver cancer. This randomized phase III trial is studying giving combination chemotherapy together with amifostine to see how well it works compared to combination chemotherapy alone in treating patients with liver cancer.
Interventions
- DRUG cisplatin
- PROCEDURE therapeutic conventional surgery
- DRUG fluorouracil
- DRUG amifostine trihydrate
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 1999-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003994
The ClinicalTrials.gov registry entry for NCT00003994 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003994 about?
NCT00003994 is a clinical study titled "Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer". Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. It is not yet known which ...
What is the current status of trial NCT00003994?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 277 participants. The study started on 1999-03.
What interventions are being tested in trial NCT00003994?
The interventions under investigation include: cisplatin (DRUG), therapeutic conventional surgery (PROCEDURE), fluorouracil (DRUG), amifostine trihydrate (DRUG), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00003994?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.